Chairs: Selim Badur
Professor, Department of Microbiology, Division of Virology and Immunology, Istanbul University Medical School, Istanbul, Turkey
Director, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
Professor of Medicine and Stuart S. Richardson Professor of Clinical Virology, University of Virginia School of Medicine, Charlottesville, Virginia, USA; Influenza Research Coordinator, The Wellcome Trust, London, United Kingdom
Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA
Professor of Virology, Erasmus MC, Rotterdam, The Netherlands
Scientific Advisory Board:
Rick Bright
Biomedical Advance Research and Development Authority, Washington, DC, USA confirmed
Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey confirmed
Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands confirmed
University of Tennessee, Memphis, Tennessee, USA confirmed
National Heart & Lung Institute, Imperial College, London, United Kingdom confirmed
University of Tokyo, Tokyo, Japan; University of Wisconsin, Madison Wisconsin, USA; University of Tokyo, Tokyo, Japan confirmed
Department of Microbiology, The University of Hong Kong, Pokfulam, Hong Kong SAR, China confirmed
Vanderbilt University School of Medicine, Nashville, Tennessee, USA confirmed
Armed Forces Health Surveillance Center, Silver Springs, Maryland, USA confirmed
Infectious Diseases, University of Singapore Hospital, Singapore confirmed
Day One Friday, 23 March 2012 Registration Desk Opens
Welcome – Cathryn Macrae, The Macrae Group LLC, and The Macrae Foundation confirmed
Keynote Address – Risk Assessment of New Emerging Novel Respiratory Viruses…. - Nancy Cox, Director, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA confirmed Session I Minisymposium: Animal/Human Interface – Chair: Albert Osterhaus, Professor of Virology, Erasmus MC, Rotterdam, The Netherlands
The Role of Birds in Pandemic Influenza – Giovanni Cattoli, Istituto Zooprofilattico Sperimentale delle Venezie, Padova, Italy confirmed
The Role of Swine Influenza – Richard Webby, Infectious Diseases, St Jude Children’s Research Hospital, Memphis, Tennessee, USA confirmed
New Viral Pathogens Discoveries in Bats – Christian Drosten, Clinical Virology Section, Bernhard-Nocht-Institut, Hamburg, Germany invitedOral Presentation
Rates and Patterns of Genomic Reassortment of Influenza Viruses in North American Swine – Martha Nelson, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, United States of American confirmedOral Presentation - Young Investigator Award Recipient Sponsored by The Macrae Group LLC
Cross-species Transmission of Pandemic Influenza (pH1N1) Virus in Backyard Pig Farms in Semirural Communities in Tumbes, Peru – Yeny Tinoco, US Naval Medical Research Unit – Six, Lima, Perú confirmed Session II Virology/Diagnostics –Chair: Malik Peiris, Department of Microbiology, University of Hong Kong, Hong Kong SAR, China 12.10 – 12.35
Multi- Respiratory Diagnostic Platform – TBD
Paramyxovirus Virus: A Never-Ending Story – Albert Osterhaus, Professor of Virology, Erasmus MC, Rotterdam, The Netherlands confirmed
Novel Diagnostic Technologies – David Murdoch, University of Otago, Christchurch, New Zealand confirmed
15.20 – 15.40 –New Generation PCR under Multiplex Assays - David Ecker, Ibis Biosciences,an Abbott Company, Carlsbad, California, United States confirmed
15.40 – 16.00 – Molecular Diagnostics Assays – Karen Young, Roche Molecular Systems, Inc., Pleasanton, CA, United States invitedOral Presentation - Young Investigator Award Recipient Sponsored by The Macrae Group LLC
Characterization of the Fitness Impairments Induced by the H275Y Oseltamivir-resistance Mutation in the Influenza A/Brisbane/59/2007 and 2009 Pandemic H1N1 Backgrounds – Catherine Beauchemin, Ryerson University, Toronto, Canada confirmedOral Presentation
Detection of Viruses by Real Time RT-PCR in Children with Acute Respiratory Tract Infection (ARI) from a Rural Community in India – Shobha Broor, All India Institute of Medical Sciences, Delhi, India
Oral Presentation - Young Investigator Award Recipient Sponsored by The Macrae Group LLC
Detection of Polymorphisms at Residue 222 of the Pandemic Influenza A/H1N1 Hemagglutinin at Quasi-species Level: Association with Severe Cases – Paola Cristina Resende, Laboratory of Respiratory Viruses and Measles, Oswaldo Cruz Institute, Rio de Janeiro, Brasil confirmed Session III Pathogenesis – Chair: Yoshihiro Kawaoka, University of Wisconsin, Madison Wisconsin, USA; University of Tokyo, Tokyo, Japan 16.45 – 17.05
Literature Review – Pre-Clinical SARS and Influenza - Malik Peiris, Department of Microbiology, University of Hong Kong, Hong Kong SAR, China confirmed
Literature Review – Pre-Clinical Rhinovirus and other Respiratory Viruses - Sebastian Johnston, National Heart & Lung Institute, Imperial College, London, United Kingdom confirmed
Measles Immune Suppression: Lessons from the Macaque Model– Rik De Swart, Erasmus MC, Department of Virology, Rotterdam, The Netherlands confirmed 18.00 – 19.30 Welcome Reception Saturday 24 March 2012
Session III Pathogenesis – Chair: Yoshihiro Kawaoka, University of Wisconsin, Madison Wisconsin, USA; University of Tokyo, Tokyo, Japan (continued)
New Insights from Studies on Influenza –Yoshi Kawaoka, University of Tokyo, Tokyo, Japan; University of Wisconsin, Madison, Wisconsin, USA confirmed
Immunopathogenesis Implications for RSV – Fernando Polack, Division of Infectious Disease, Vanderbilt University School of Medicine, Nashville, Tennessee, USA confirmed
Surprise H5N1 – Sander Herfst, Department of Virology, Erasmus MC, Rotterdam, The Netherlands confirmed Oral Presentation
The PB1-F2 Protein Proapoptotic Sequence Contributes to Influenza A Virus Pathogenicity and Predisposition to Secondary Bacterial Infection – Irina V. Alymova, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States of America confirmedOral Presentation
The Influence of Smoking on Pulmonary Influenza Infection – an Ex vivo Study
John M. Nicholls, The University of Hong Kong, Pok Fu Lam, Hong Kong confirmedOral Presentation
Deficient Antiviral Responses to Influenza in Primary Bronchial Epithelial Cells of Chronic Obstructive Pulmonary Disease – Peter AB Wark, Centre for Asthma and Respiratory Disease, Hunter Medical Research Institute, University of Newcstle, New South Wales, Australia
Session IV Epidemiology/Impact – Chair: Arnold Monto, Thomas Francis Jr Professor of Epidemiology, University of Michigan, Ann Arbor, Michigan, USA
Special Invited Lecture: Lessons Learned from H1N1 Pandemic – Sylvie Briand, Influenza, Respiratory Diseases, Hepatitis, PIP framework (IRD/PED) Health Security and Environment (HSE), World Health Organization, Geneva, Switzerland
Coffee Break
Burden of Disease of Respiratory Viral Infections, a Geographical Prospective – W. Abdullah Brooks, Director Kamalapur Field Site, Head Infectious Diseases Unit (ICDDR,B), Johns Hopkins Bloomburg School of Public Health, Dhaka, Bangladesh and Baltimore, Maryland, USA confirmed
Estimating the Global Impact of Influenza - Marc Alain Widdowson, Division of Viral Disease, Center for Disease Control, Atlanta, Georgia, USA confirmed 13.05 - 15.05 Lunch Break
Importance of Respiratory Viral Diseases in Turkey – Selim Badur, Department of Microbiology, Division of Virology and Immunology, Istanbul University Medical School, Istanbul, Turkey confirmed
Burden of RSV in the Elderly – Ann Falsey, University of Rochester, Rochester, New York, USA confirmed Oral Presentation
The Role of Respiratory Viruses in Lower Respiratory Tract Infections in Primary Care – Frank E. J. Coenjaerts, University Medical Center Utrecht, The Netherlands confirmedOral Presentation
Respiratory Viruses in Airline Travelers with Influenza Symptoms: Results of an Airport Screening Study – Lance C. Jennings, Canerbury Health Laboratories, University of Otago, Christchurch, New Zealand
Oral Presentation
Molecular Epidemiology of Adenovirus 4 and 7 Infections of Military Recruits in Training during the 15 Years with no Vaccination Program (1997-2011) – Adriana
Kajon, Lovelace Respiratory Research Institute, Albuquerque, New Mexico, USA confirmedOral Presentation
A Retrospective, Observational Study on Incidence, Influenza-Associated Complications, and Treatment Patterns of Influenza in the United States: 2006–2010 Influenza Seasons – Philip Spagnuolo, Genentech, Inc., South San Francisco, California, USA confirmedOral Presentation
Spatial Epidemiology of Respiratory Syncytial Virus (RSV) in the USA – Cécile Viboud, Fogarty International Center, National Institutes of Health, Bethesda, Maryland, USA
Poster Review - Albert Osterhaus, Erasmus MC, Rotterdam, The Netherlands confirmedWine/Cheese Reception & Poster Session Day Three Sunday, 25 March 2012
Session V Clinical – Frederick Hayden, Professor of Medicine and Stuart S. Richardson Professor of Clinical Virology, University of Virginia School of Medicine, Charlottesville, Virginia, USA; Influenza Research Coordinator, The Wellcome Trust, London, United Kingdom
Literature Review: Clinical Papers Adults + discussion– Frederick Hayden,
Professor of Medicine and Stuart S. Richardson Professor of Clinical Virology, University of Virginia School of Medicine, Charlottesville, Virginia, USA; Influenza Research Coordinator, The Wellcome Trust, London, United Kingdom confirmed
Literature Review: Clinical Papers Children + discussion – Susanna Esposito, Department of Maternal and Pediatric Sciences, University of Milan, Milan, Italy confirmed
Severe Manifestation of H1N1 – Jordi Rello, Critical Care Department, University Hospital Vall d’Hebron, Barcelona, Spain confirmed 10.30 – 11.00 Coffee Break Session VI Antivirals and Therapeutics – Chair: Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands
Antivirals for Respiratory Viruses Overview – Menno de Jong, University of Amsterdam, The Netherlands confirmed
RNA Interference Strategies for Respiratory Virus Infection – John DeVincenzo, University of Tennessee, Memphis, Tennessee, USA confirmed
Respiratory Viral Infections- Monoclonal Antibodies – TBDOral Presentation
The Influenza Resistance Information Study (IRIS): Patterns and Predictors of Antiviral Drug Treatment – Drew GriffinLevy, Genentech, South San Francisco, California, USA
Oral Presentation
A Systematic Review on the Impact of Neuraminidase Inhibitor Antiviral use on Outcomes of Public Health Importance during the 2009/10 (Swine) Pandemic Influenza A/H1N1v – Stella Muthuri, University of Nottingham, United Kingdom confirmedOral Presentation
Clinical and Virological Response to Oseltamivir in Infants <1 year with Influenza
Barbara Rath, Charité University Medical Center, Berlin, Germany confirmedSymposium Adjourns for the Day – free afternoon and evening Monday, 26 March 2012 Session VI Antivirals and Therapeutics – Chair: Menno de Jong, Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands (continued) 09.00 – 09.15 Oral Presentation
Macrolides and Anti-Inflammatory Agents in the Treatment of Avian Influenza (H5N1) – Stephen Toovey, Academic Centre for Travel Medicine & Vaccines, Royal Free and University College Medical School, London, United Kingdom
Oral Presentation
Pharmacokinetic-pharmacodynamic (PK-PD) determinants of oseltamivir efficacy using data from two Phase 2 inoculation studies – Craig Rayner, Roche Products Pty Ltd, South Melbourne, Australia
Session VII Vaccinology/Prevention – Chair: Nancy Cox, Director, Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA
New Vaccines for Respiratory Virus Infections – Adolfo Garcia-Sastre, Mt Sinai School of Medicine, New York, New York, USA confirmed
How do we Deal with Guillian-Barre Syndrome, Narcolepsy and Other Adverse Events Post Vaccination – David Salisbury, Director of Immunisation, Department of Health, London, United Kingdom confirmed
Update on Novel Influenza Vaccines from the WHO Meeting – Rick Bright, Influenza Division, Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness and Response, U.S. Department of Health and Human Services, Washington, D.C. confirmed 10.45 – 11.00 Oral Presentation
A Novel RSV Genetic Vaccine Candidate based on Chimpanzee Adenovirus and MVA Vectors is Safe and Highly Immunogenic in Rodents and Primates and fully Protects Cotton Rats from RSV Challenge – Alessandra Vitelli, Okairos Srl, Pomezia, Rome, Italy confirmedOral Presentation
Monoclonal Antibodies Cross-reacting with the Neuraminidase of Seasonal and 2009 Pandemic H1N1 Influenza Viruses – Hongquan Wan, Laboratory of Respiratory Viral Diseases, US Food and Drug Administration, Bethesda, Maryland, United States of America
Oral Presentation
Efficacy of Seasonal Influenza Vaccination in Children in Hong Kong: a Randomized Controlled Trial – Benjamin J. Cowling, School of Public Health, The University of Hong Kong, Pokfulam, Hong Kong
Oral Presentation
Safety and Immunogenicity of a Recombinant RSV F Protein Nanoparticle Vaccine Manufactured in Insect Cells: a Phase I Dose and Formulation-finding Trial in Adults – Gregory Glenn, Novavax, Inc., Rockville, Maryland, USA
Oral Presentation
Immunogenicity and Safety of H1N1 Vaccination in Adults aged 19–40 years Vaccinated with Seasonal Influenza Vaccine 4 months Previously – Sumita Roy-Ghanta, GlaxoSmithKline Biologicals, King of Prussia, Pennsylvania, USA confirmed 12.45 – 13.15 Closing Panel: Cathryn Macrae, Selim Badur, Nancy Cox, Ab Osterhaus, Arnold Monto, Fred Hayden
Eficacia de las drogas antidemencia: Intentando un análisis objetivo Jorge González, Alfonso Sánchez, Rommy von BernhardiEscuela de Medicina, Pontificia Universidad Católica de Chile. Se realizó una revisión bibliográfica referente a la eficacia de las drogas anti-demencia más aceptadas y que se encuentran disponibles en Chile. Los inhibidores de lacolinesterasa, rivastigmina y d
‘on-line fraud, behind enemy lines’ by Ian Ross Online and corporate fraud remains a serious concern for global Business. But this paper argues that part of the problem in tackling the ever evolving nature of fraud comes from the very techniques and approaches used to prevent it. The global market research and survey company „Frost & Sullivan‟ estimate that there are 2.28 milli